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Abstract 
Chromosome Iq gain is commonly found in hepatocellular carcinoma (HCC) 
(46%—86%). In array CGH analysis, GEF-Hl, located on chromosome lq22 was found to 
show copy number gain in 5/8 HCC samples (3 HCC biopsies & 5 HKCI-series of in-house 
established HCC cell lines). Quantitative RT-PCR further showed that two third (66/100) 
of HCC primary tissues and 92% (12/13) of HCC cell lines exhibit high expressions of GEF-
Hl . GEF-Hl, also known as ARHGEF2, is a Rho guanine nucleotide exchange factor which 
regulates the activities of Rho-GTPase and controls many cellular functions such as cell 
motility, cell proliferation, cell differentiation and controlling epithelial cell permeability. 
In this study, I focused on the underlying mechanism of GEF-Hl activation and its 
cellular functions in HCC development and progression. 
Using Fluorescence in situ hybridization (FISH) and copy number assays, copy 
gain of GEF-Hl was commonly detected in HCC cell lines and primary tumors examined. 
In exon sequencing analysis of 10 HCC cell lines and 10 pairs of primary tumor and their 
adjacent non-tumoral liver, oncogenic C53R mutation of GEF-Hl was not detected, 
suggesting that copy number gain is likely a main activating mechanism of GEF-Hl in 
HCC. In in-vitro functional study, two stable clones expressing GEF-Hl were established 
from immortalized hepatocyte cell line, MIHA. Results of MTT and BrdU assays showed 
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that ectopic expression of GEF-Hl promoted cell viability and cell proliferation, 
respectively. Also, cells expressing GEF-Hl showed greater migratory and invasion 
abilities which were RhoA-independent. 
In addition, GEF-Hl overexpressed cell had attenuated level of E-cadherin and 
upregulation of E-cadherin transcription repressors. Most of epithelial markers, 
including alpha-E-catenin, gamma-catenin, cytokeratin 18 and claudin, were 
downregulated together with the increased level of mesenchymal marker vimentin in 
GEF-Hl expressing cells. All these results suggested that GEF-Hl may contribute to the 
epithelial to mesenchymal transition (EMT), which is a common event in many types of 
cancer. In in-vivo study, GEF-Hl induced tumorigenicity of Ml HA, leading to tumor 
formation in nude mice. Taken together, the data from this thesis demonstrated that 
GEF-Hl is a gene commonly overexpressed in HCC, where it promotes cell motility 




在肝細胞癌（H C C )中，染色體 1 q擴增是很常見的（佔 4 6 % - 8 6 % ) �通過微 
陣列比較基因組雜交實驗分析 ’ 8個H C C病例（ 3個H C C活檢組織， 5個H K C I系列 
的細胞株）中有5個發現了位於染色體1 q 2 2的G E F - H I有上調。計量R T - P C R結果 
進一步展示’三分之二（66/100)的HCC組織和92% ( 1 2 / 1 3 )的H C C細胞株高表達 




在營光原位雜交（ F I S H )和拷貝數目實驗中，所有被檢驗的H C C細胞抹及 
H C C組織中均顯示G E F - H 1的拷貝數目增加，但是G E F - H I的外顯子測序分析實驗顯 
示在1 0個H C C細胞株或者1 0對腫瘤及周邊非腫瘤組織中並無發現致癌性C 5 3 R外 





此外，G E F - H 1過度表達的細胞可以降低 E - c a d h e r i n的水準以及上調 E -
c a d h e r i n的轉錄抑制子。在G E F - H I過度表達的細胞中，絕大部份的上皮標記物會 
下調，包括 alpha-E-catenin，gamma-eaten i n， c y t o k e r a t i n 18 和 c laud in，同 
時間質標記物v i m e n t i n水準上調。所有這些結果均顯示 ’ GEF-H1對於上皮間質轉 
變（E M T )這個在多種癌癥中常見的事件可能有重要作用。體内實驗結果顯示， 
GEF-H1誘導MIHA細胞棟中腫瘤的發生，從而在棵鼠體内形成腫瘤。綜上所述，我 
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Chapter 1: Inrtroduction 
Chapter 1: INTRODUCTION 
1.1. Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) accounts for up to 90% of the primary liver 
cancer. HCC was the sixth most common cancer and the third-leading cause of cancer-
related deaths worldwide in 2008 (Figurel.l). The Asian and Middle-Western Africa 
regions had the highest incidence and mortality rates (Figurel.2), and the geographical 
distribution of the mortality rates was similar to that of the incidence rates, 
demonstrating the poor prognosis of this cancer. Independent of the region, the 
incidence rate of male was higher than that of female and the overall ratio of male to 
female was 2.4:1 in 2008 (Figurel.3) (GLOBOCAN 2008). 
In Hong Kong, liver cancer incidence rate (25/100,000, 1750 new cases) was 
ranked 4 and the mortality rate (21.5/100,000,1500 deaths) was ranked 3 in 2008 
(Figurel.4). From the statistic data for male gender, liver cancer was the forth common 
cancer and was the second rank for the total cancer deaths in Hong Kong (Figurel.5). 
The ratio of male to female incidence and mortality rate were both about 3:1 in HK 
(Figurel.6) (Hong Kong Cancer Registry 2008, Hong Kong Hospital Authority). 
Because the symptoms of HCC are not obvious in the early stages and the tumor 
growth is rapid, most of the HCC cases cannot be diagnosed at the early stages so that 
the best time for curative treatment are usually missed. This makes the overall survival 
rate of HCC is extremely low (3-5%). The choice of HCC treatment is depended on the 
tumor stage, tumor size and the existing liver functions (Figurel.7) (Rahbari NN 
et.al.,2011). Resection, orthotopic liver transplantation (OLT), percutaneous ethanol 
injection (PEI) and radiofrequency ablation (RFA) are able to cure HCC in the early stage. 
In later stage, embolization with chemical or radioactive substance can obstruct the 
hepatic artery and kill the cancer cells, which get the blood supply mainly from hepatic 
artery. Traditional chemotherapies are not effective to HCC due to the multi-drug 
2 
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resistance protein family (MDR-1), poor drug delivery and dose limitations from 
underlying liver dysfunction in HCC. Since 2007, a multi-kinase inhibitor sorafenib 
targeting serine-threonine and tyrosine kinase (Raf-1, VEGFR2, PDGFR, FLT3, Ret, and c-
Kit) have been used to cue the advanced stage of HCC. Sorafenib prolongs the life and 
brings a hope to the later stage patients, although the overall survival is still short (10.7 
months) (Liu L et.al., 2006; Cabrera R, Nelson DR, 2010). 
3 
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Figurel.l (A) Number of incidence and (B) number of death of different cancers 
worldwide in 2008. HCC was the sixth most common cancer and third-leading cause of 
cancer-related deaths worldwide. 
Source: FerlayJ, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: 
lARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: 
http://globocan.iarc.fr 
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Figurel.2 The global (A) incidence and (B) mortality rates of HCC in 2008. The Asian 
and Middle-Western Africa regions had the highest incidence and mortality rates of HCC 
Source: FerlayJ, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: 
lARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: 
http://globocan.iarc.fr 
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Figurel.3 Male and female incidence and mortality rates of HCC (per 100,000) in 2008 
in different regions. The incidence and mortality rates of male were generally higher 
than that of female. 
Source: FerlayJ, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: 
lARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: 
http://globocan.iarc.fr 
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Figurel.4 (A) Incidence rate and (B) mortality rate of different cancers (per 100,000) in 
Hong Kong in 2008. HCC was the forth most common cancer and third-leading cause of 
cancer-related deaths in Hong Kong. 
Source: Hong Kong Cancer Registry 2008, Hong Kong Hospital Authority 
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Figurel.5 (A) Incidence rate and (B) mortality rate of different cancers (per 100,000) 
for male gender in Hong Kong in 2008. HCC was the forth most common cancer and 
second-leading cause of cancer-related deaths in male gender in Hong Kong. 
Source: Hong Kong Cancer Registry 2008, Hong Kong Hospital Authority 
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Figurel.6 The number of incidence and number of death cases of HCC in Hong Kong in 
2008 for different genders. The ratio of male to female incidence and mortality rate 
were both about 3:1. 

























































































































































































































































































































































































































Chapter 1: Introduction 
1.1.1. Etiological factors 
The development of hepatocellular carcinoma (HCC) is a multi-step process associated 
with changes in host tumor-progressing gene expression (Feitelson MA, 2002) 
(Figurel.8). There are many etiological factors account for these genetic changes 
(Figurel.9). It includes liver cirrhosis, hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infection, chronic alcohol consumption, non-alcohol steatohepatitis (NASH), male 
gender and aflatoxin B1 exposure (Nordenstedt H et.al., 2010). 
. . , Chemical 
Chronic viral ^ . 
^ Carcinogens 
hepatitis 
” ” ^"""" •…‘丨 / x D 
/
Normal Initiated FAH Dysplastic WD-HCC MD-HCC POHCC 
cell cell nodule 
disorders • > 
Genomic instability Accumulation of genetic damage 
Figurel.8 The development of hepatocellular carcinoma (HCC) is a multistep process 
associated with changes in host tumor-progressing gene expression. Chronic viral 
hepatitis, alcoholic cirrhosis, genetic disorders, chemical carcinogens and liver injury 
may cause genomic instability in liver cells which may cause clonal expansion of initiated 
cell to form FAH and dysplastic nodules. Some of FAH and dysplastic nodules can 
undergo phenotypic reversion while some of them continuously accumulate genetic 
damage that lead to WD-HCC, MD-HCC and then PD-HCC. FAH: foci of altered 
hepatocytes; WD-HCC: well differentiated HCC; MD-HCC: moderately differentiated HCC; 
PD-HCC: poorly differentiated HCC 






























































































































Chapter 1: Inrtroduction 
1.1.1.1. Chronic Hepatitis and Liver Cirrhosis 
Cirrhosis is found in 80-90% of HCC cases and is the largest single risk factor, 
although not all HCC cases are related to cirrhosis and chronic inflammation (Rocken C 
et.al., 2001). Cirrhosis can be due to chronic hepatitis infection (HBV and HCV), chronic 
alcohol consumption, non-alcohol steatohepatitis (NASH), and the activation of hepatic 
stellate cells (HSCs). HSCs become activated during the progression of liver injury and 
the activation of HSCs undergoes transdifferentiation to fibrogenic myofibroblast-like 
cells (Moreira RK., 2007). This transformation produces extracellular matrix, which is the 
hallmark of hepatic fibrosis. Unchecked progression of fibrosis ultimately eventuates in 
irreversible cirrhosis. 
1.1.1.2. H B V 
An estimated 350 million people worldwide are chronically infected with HBV 
and up to 40% of these carriers will develop complications of cirrhosis and HCC (Lee WM, 
1997). About 53% of HCC cases in the world are estimated to be related to HBV 
(LupbergerJ, Hildt E, 2007). 
HBV is a virus with partially double stranded-DNA in its 3.2kb genome. The viral 
genome is packed into an envelope with hepatitis B surface antigen (HBsAg) (Figurel.lO). 
The viral genome encodes the genes of reverse transcriptase, DNA polymerase (pol), 
HBsAg, envelop proteins (LHBs, MHBs and SHBs) and transactivating protein, HBx. 
HBV likely causes HCC via both indirect and direct pathways (Figurel. l l ) . 
Indirectly, HBV induces chronic injury in liver cells that inflammation and regeneration 
activities occur. The irregular regeneration of hepatocytes is an important factor that 
associates with hepatocarcinogenesis (Ueno Y et.al, 2001). Because it increases the 
hepatocyte turnover and facilitates successive acquisition of genomic alterations, 
escaping the repair mechanisms and promoting malignant transformation and clonal 
13 
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expansion, finally results in HCC development. Early infection of HBV allows more time 
for inflammation so that higher chance for the transformation occur. (Fung J et.al., 2009) 
In the direct pathway, firstly, HBV DNA can integrate into the host genome. This 
integration can be found in about 85-90% of HBV-related HCC and the integrated viral 
DNA sequence are the same in individual tumor (Bonilla Guerrero R, Roberts LR., 2005). 
Integrations usually occur at multiple random sites and cause mutagenic consequences, 
including large inverted duplications, deletions, amplifications and translocation, 
resulting in chromosomal instability (Kremsdorf D, 2006). Although it is rare, HBV DNA 
can integrate into the sites near the oncogenes such as hTERT, MAPKl, cyciine A and the 
gene for tumor necrosis factor receptor-associated protein 1 which regulate cellular 
immortalization, cell proliferation, differentiation and cell viability (Bonilla Guerrero R, 
Roberts LR., 2005). 
Secondly, HBV encoded protein, HBx, is expressed in 70% of patients with HBV-
related HCC and over 95% of patients with HBV-related cirrhosis and dysplasia are 
positive for HBx (Fung J et.al., 2009). HBx protein is a transcription activator that can 
interact with many host regulatory elements such as major histocompatibility complex, 
epidermal growth factor receptor, c-myc, c-jun, c-fos, AP-1, NF-kB and S P l (Rossner MT, 
1992; Yeh CT, 2000; Waris G, Siddiqui A, 2003). These interactions may result in 
interference on the hepatocyte DNA repair system and the cell proliferation mechanism 
(Becker SA, 1998). Also, HBx interacts with p53 and causes transcriptional repression of 
p53 gene (Lee SG, Rho HM, 2000), resulting in interfering p53-dependent functions such 
as apoptosis, cell-cycle regulation, DNA repair and tumor suppression (Kremsdorf D, 
2006). 
Apart from HBx gene, truncated pre-S2/S gene also can integrate into the host 
genome and contribute to the development of HCC. Pre-S2/S gene encodes for preS2 
transcription activators, which is phosphorylated by protein kinase C, and resulting in 
activation of transcription factors AP-1 and NF-kB (Fung J et.al., 2009). 
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Figurel.lO The schematic structure of Hepatitis B virus. LHBs, MHBs and SHBs are 
envelope proteins; HBsAg is hepatitis B surface antigen; Pol is DNA polymerase. 
Figure adapted from Stephanie Schadler, Eberhard Hildt, 2009. 
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Figurel. l l Both HBV and HCV induce hepatocarcinogenesis through direct and indirect 
mechanisms. Indirectly, HBV and HCV promote the chronic hepatitis and liver cirrhosis 
that increases the probability of cell transformation and HCC development. Directly, 
HBV genes insert into the host genome while HBV and HCV proteins interact with host 
proteins and components that may promote the cell transformation. 
Figure adapted from Fung J et.al., 2009. 
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1.1.1.3. HCV 
HCV is estimated to infect 170 million people worldwide and approximately 20% 
of them will progress to cirrhosis (Alter MJ, 1995). About 1-3% of patients chronically 
infected with HCV will develop HCC after 30 years (Niederau C, 1998). There is an 
increasing incidence of cases of HCC observed in the Western population. HCV has been 
the dominant viral cause of HCC in North America, Western countries and Japan 
(Nordenstedt H, 2010). 
HCV is a positive-stranded RNA virus that has approximately 9.5 kb. The genome 
encodes for three structural proteins at the N-terminal and four nonstructural 
functional proteins at the C-terminal. The structural proteins are the core (C) and 
envelope 1 and 2 proteins (E l and E2) while the nonstructural (NS) proteins include NS2, 
NS3, NS4 and NS5 (Figurel.l2). 
HCV does not encode reverse transcriptase gene so HCV is unable to integrate 
into the host genome. It is a cytoplasmic-replicating virus that induces chronic 
inflammation, cirrhosis and HCC through indirect pathway (Figurel.ll). It is rare for 
chronic hepatitis C patients develop HCC directly without cirrhosis and the presence of 
cirrhosis is almost a pre-requisite for HCV-induced HCC development (Fung J et.al., 
2009). 
HCV proteins also contribute to the development of HCC through the direct 
pathway. The core protein, apart from its normal functions of viral particle assembly and 
generation of complete virions, is involved in cell signaling, transcription activation, 
apoptosis, lipid metabolism, transformation, cellular proliferation, cell cycle control and 
tumor formation (Lai MM, Ware CF, 2000). The core protein binds to p53 and pRb tumor 
suppressor proteins and regulates the expression of p21/Waf, which is involved in the 
cell cycle control and regulates the transcription by interacting with cytoplasmic signal 
transduction molecules (Kwun HJ, Jang KL, 2003). The E2 protein inhibits T and natural 
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killer (NK) cells, promoting cell survival and proliferation via interacting with CD81. NS3 
protein, which is a multifunctional protein with protease, RNA helicase and NTPase 
activity, promotes hepatocarcinogenesis by interacting with certain cellular proteins 
such as p21 and p53 (Kwun HJ et.al., 2001). NS5A is membrane associated protein 
involved in the HCV genome replication. After truncation, NS5A translocate to the 
nucleus and acts as a transcriptional activator. NS5A also interacts with cellular signaling 
components such as growth factor receptor-bound protein 2, p53, p21/waf and cell 
cycle-regulatory kinases, resulting in inhibition of apoptosis (Reyes GR, 2002) 
(Figurel. l l ) . 
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Figurel.12 (A) Schematic diagram of HCV shows the core and envelope 1 and 2 
structural proteins (El and E2) (B) The genome of HCV encodes structural and non-
structural parts. 
Sources: (A) Ryan KJ, Ray CG: Sherris Medical Microbiology, 5 th Edition: www.accessmedicine.com. Copyright © The McGraw-Hill 
Companies, Inc. All rights reserved. (B) Expert reviews in molecular medicine, Vol. 5; 19 November 2003, ©2003 Cambridge 
University Press, http://www.expertreviews.org/ 
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1.1.1.4. Male gender 
In almost all populations, male has higher liver cancer incidence and mortality 
rates than female, with male to female ratios usually between 2:1 and 4:1, and the 
overall incidence sex ratio of male: female is 2.4:1 (GLOBOCAN 2008). Positive roles of 
androgen and negative roles of estrogen on hepatocarinogenesis are the two main 
factors for this different incident between genders (sex disparity) (Yeh SH, Chen PJ., 
2010). 
Increased androgen activity is significantly associated with the increased risk of 
HCC in male HBsAg carriers (Yu MW et.al., 2001). The involvement of the androgen 
receptor pathway in male hepatocarcinogenesis has been well demonstrated that 
knockout of androgen receptor in hepatocytes delayed the development of DEN-
induced HCC and decreased the number of liver tumors formed in mouse model, 
suggesting the positive role of androgen in hepatocarcinogensis (Ma WL et.al., 2008). 
Also, HBx activates the N-terminal transactivation domain of the androgen receptor and 
enhances androgen receptor dimerization, by inhibiting the glycogen synthase kinase-3 
(GSK-3b) activity. These two actions together activate the activities of androgen 
receptor, hence increased risk of HCC (Yang WJ et.al., 2009). 
In female, the estrogen-mediated downregulation of IL-6 is critical for the gender 
disparity of HCC (Naugler WE et.al., 2007). Since sex disparity occurs from the stage of 
chronic hepatitis, the antitumor functions start to be different from this early 
inflammation stage. The macrophages (Kupffer cells), T cells, and other immune cells are 
recruited to the microenvironment and release the pro-inflammatory factors, including 
the chemokines and cytokines such as IL-6. (Mantovani A et.al., 2008) These factors 
target and activate several transcriptional activators within the hepatocytes, including 
NF-KB, signal transducer and activator of transcription 3 (STATS), and hypoxia-inducible 
factor-la (HIF-la) (Mantovani A et.al., 2008). All these factors not only increase the 
tumorigenic activity of hepatocytes, but also lead to further production of the 
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inflammatory mediators. Therefore, estrogen could protect hepatocytes from malignant 
transformation via downregulation of the secretion of these pro-imflammatory factors. 
1.1.1.5. Aflatoxin B1 exposure 
Aflatoxins are mycotoxins from Aspergillus flavus and Aspergillus parasiticus, and 
are potent naturally occurring carcinogens. They are common in the hot and humid 
conditions, particularly in Asia and sub-Saharan Africa. They are usually found in spoiled 
food such as grains, corns, peanuts and soya beans (McKillop IH et.al., 2006). The 
aflatoxin B1 can be converted to exo-8,9-epoxide by cytochrome p450 enzyme. This 
product reacts with guanine nucleotide in DNA to form DNA adducts, which can lead to 
heritable genetic changes and enhance the transformation of hepatocyte (Smela ME 
et.al, 2001) (Figurel.13). 
GC->TA transversion is the most prevelant mutation under the effect of aflatoxin 
Bl . Significantly, tumor suppressor gene p53 is frequently found to have GC—TA 
mutation of the third position at codon 249, resulting in Arginine-^Serine alteration in 
the exon 7, which is a mutation hotspot in many cancers, including HCC. Evidences show 
that A249S mutation of p53 promotes cell proliferation, giving growth advantage of 
cancer cells. However, the effect of aflatoxin B l on p53 mutation has not been directly 
demonstrated (Smela ME et.al, 2001; Dumenco L et.al., 1995). 
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Figurel.l3 Formation of DNA adduct from aflatoxin Bl. 
Figure adapted from Smela ME et.al.,2001. 
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1.2. Genomic abnormalities in HCC 
HCC is a heterogeneous tumor with lots of chromosome changes, including 
chromosomal truncation, deletion, amplification and translocated to other 
chromosomes (Debernardi S et.al., 2004). Genomic abnormalities play an important role 
in the carcinogenesis of HCC. Most of the chromosome aberrations are random 
processes, although some of them are specific for tumorigenesis. These aberrations may 
lead to the inactivation of tumor suppressor genes or activation of oncogenes. In HCC, 
chromosomal gains are often found at chr.lq (46%—86%), 6p (20%-33%), 8q(31%-83%), 
17q (29%-48%), and 20q (5%-37%) while chromosomal losses are frequently found at 
chr.lp (36%—37%), 4q (32%—70%), 6q (19%—37%), 8p (26%-77%), 13q (16%-55%), 16p 
(14%-70%), and 17p (10%-60%) (Chen L et.al., 2010). It has been reported that gains of 
chromosome lq21-23 and 8q22-24 are associated with early stage of HCC 
development (Wong N et.al, 1999) and lost of chromosome 8p has an important role in 
HCC metastasis (Qin LX et.al, 1999). Chr.lq gain is the most frequent genomic alteration 
in HCC, in which chromosome lq21-22 gains were found in 40% of advanced metastatic 
HCC (Chen L et.al., 2010). A number of oncogenes have been identified in this region, 
including CREB3L4, INTS3, SNAPAP, JTB, SHCl, CKSIB, CHDIL and GEF-Hl (Inagaki Y 
et.al., 2008; Wong N et.al., 2003; Wang XC et.al., 2009; Ma NF et.al., 2008; Cheng IK 
et.al., unpublished data). 
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1.3. GEF-Hl 
GEF-Hl is located in chr.lq22. It is a Rho guanine nucleotide exchange factor that 
exchanges GDP for GTP to activate Rho GTPase. GEF-Hl associates with microtubules in 
many types of non-polarized cells such as Hela cells (Krendel M et.al., 2002). It is in 
inactive form when it associates with microtubules, and is activated after it is released 
when microtubules depolymerize (Figurel.l4). 
GEF-Hl is composed of 985 amino acids with molecular weight about 120kDa. 
There are mainly 5 domains, including C I domain, DN-homology (DH) domain, Plextrin 
homology (PH) domain, coiled-coil domains and proline-rich regions. C I domain is a 
zinc-finger motif-containing region, mutation of a cysteine residue (C53R) in this domain 
or deletion of this domain abolishes the binding ability of GEF-Hl to the microtubule 
and thereby increases GEF-Hl enzymatic activity (Krendel M et.al., 2002). DH domain is 
the catalytic domain that is conserved in all members of Rho-GEF family and in GEF-Hl. 
PH domain is involved in microtubule binding and directs the protein to different 
subcellular compartments such as tight junctions. 
GEF-Hl is a regulator on the RhoA-dependent pathways and functions. The 
release of GEF-Hl from microtubules is a common mechanism to activate RhoA locally, 
in turn, it acts as a bimolecular switch of many signaling pathways involved in cellular 
cytoskeleton, cell cycle progression, gene transcription, cell survival, proliferation and 
differentiation (Krendel M et.al, 2002; Bakal CJ et.al., 2005; Callow MG et.al., 2005; 
Zenke FT et.al., 2004; Jaffe AB et.al., 2005; Burridge K et.al., 2004). Following the 
activation of GEF-Hl-mediated Rho-to-Rockll signaling cascade, contractile actomyosin 
structures formation was triggered and disassembly of epithelial barrier was induced, 
contributing to the physical disruption of apical junction complexes (Samarin SN et.al., 
2007). Also, GEF-Hl was demonstrated to regulate epithelial barrier permeability and 
promoted F-actin meshworks formation in membrane ruffles and lamellipodia (Callow 
MG et.al., 2005) (Benais-Pont G et.al., 2003). 
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Figurel.l4 Depolymerization of microtubule activates the GEF-Hl and its downstream 
effector, Rho GTPase. 
Figure adapted and modified from Krendel M et.al., 2002. 
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1.4. RhoA 
RhoA is a member of Rho GTPases, which constitutes a distinct family within the 
superfamily of Ras-related small GTPases and is found in all eukaryotic cells. The activity 
of RhoA is controlled by three main factors; (1) Guanine nucleotide exchange factors 
(GEFs) catalyze exchange of GDP for GTP to activate RhoA, (2) GTPase activating 
proteins (GAPs) stimulate the intrinsic GTPase activity to inactivate the RhoA. (3) 
Guanine nucleotide dissociation inhibitors (GDIs) sequester the RhoA in their inactive 
GDP-bound conformation (Figurel.15). 
Mammalian homolog of Drosophila diaphanous (mDia) and Rho associated 
coiled-coil forming kinase (ROCK) are two major targets of RhoA (Leung T et.al., 1995; 
Ishizaki T et.al., 1996; Matsui T et.al., 1996; Watanabe N et.al., 1997). mDia is a formin 
molecule catalyzing actin nucleation and polymerization to produce long, straight actin 
filaments (Goode BL et.al., 2007) while ROCK is a serine/threonine kinase that can 
phosphorylate a variety of substrates. For example, it inactivates myosin-binding 
subunit of myosin phosphatase (Kimura K et.al., 1996; Uehata M et.al., 1997) and it 
directly phosphorylates myosin light chain (Amano M et.al., 1996). These stimulate 
cross-linking of actin by myosin and promote actomyosin contractility. ROCK 
antagonizes the action of mDia so that the cell morphogenesis, adhesion, and motility 
can be determined by the balance between mDia and ROCK activities (Narumiya S et.al., 
2009). 
RhoA is involved in numbers of cellular processes, including cell morphogenesis, 
adhesion, migration and cell cycle progression (Jaffe AB et.al., 2005 Burridge K et.al., 
2004). RhoA regulates certain type of actin cytoskeleton in the cell and modulates local 
microtubules dynamics. For instance, it regulates the stress fibers running in interphase 
cells, and the contractile ring formed in mitotic cells. 
High expression level of RhoA was observed in various human tumors, including 
26 
Chapter 1: Inrtroduction 
liver, skin and colon cancer (Fukui K et.al., 2006; Li XR et.al., 2006; Abraham MT et.al., 
2001; Fritz G et.al., 1999). High RhoA expression corresponded to progression of ovarian, 
bladder, gastric, esophageal squamous cell and testicular cancers (Horiuchi A et.al., 
2003; Kamai 丁 et.al., 2003; Pan Y et.al., 2004; Faried A et.al., 2007; Kamai T et.al., 2004). 
These strongly suggest an important role of RhoA in malignant progression of various 
tumors. In HCC, elevated RhoA level correlated with poor prognosis and recurrence 
(Fukui K et.al., 2006; Li XR et.al., 2006). 
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Figure adapted from Birkenfeld J et.al., 2008. 
28 
Chapter 1: Inrtroduction 
1.5. Epithelial-Mesenchymal Transition (EMT) 
RhoA signaling pathway was reported to control Epithelial-Mesenchymal 
Transition (EMT). RhoA stimulates the formation of stress fibers and reorganizes the 
actin cytoskeleton, generating mesenchymal phenotype under the stimulation of TGF-p 
(Kaartinen V et.al., 2002; Masszi A et.al., 2003). EMT is the conversion of epithelial cells 
to mesenchymal cells. Epithelial cells are apical basolateral polarized that they are 
closely joined by specialized membrane structures, including tight junctions, adherens 
junctions, desmosomes and gap junctions. They form a layer of cells with a basal lamina 
at the basal surface and maintain the cell-cell adhesion with their neighbors. 
Mesenchymal cells do not form apical-basolateral polarized cell layer with a basal 
lamina. Instead, they have a spindle shaped, fibroblast-like morphology with dispersedly 
contact with neighbor cells. Cultured mesenchymal cells usually have a higher motility 
and they may migrate together as chains or individual cells (Thiery JP, Sleeman JP., 
2006). 
EMT is a normal process during embryotic development in many species. In 
vertebrates, the mesenchymal cells in embryotic gastrulation allow the embryo to form 
three germ layers (ectoderm, endoderm and mesoderm) that the embryos can 
differentiate and establish more elaborate tissue structures (Thiery JP, Sleeman JP., 
2006). EMT is also a common event in a variety of cancers, including lung, breast, 
colorectal, prostate and liver cancers (Thomson S et.al., 2005; Kokkinos Ml et.al., 2007; 
Natalwala A et.al., 2008; Lawrence MG et.al., 2007; van ZijI F et.al., 2009). 
EMT is a complex process that orchestrated by numbers of pathways with many 
cross talks. TGF-p activates RhoA and its downstream target ROCK, inducing stress fiber 
formation and promoting EMT (Bhowmick NA et.al., 2001). Besides, activation of C-Met 
pathway (Fournier TM et.al., 2000; Peschard P et.al., 2001) and several growth-factor 
receptors such as fibroblast growth factor (FGF) (Valles AM et.al., 1990), insulin-like 
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growth factor (IGF) (Morali OG et.al., 2001), ERbB-2/Neu receptor (Khoury H et.al., 2001) 
and Fos estrogen receptor (Eger A et.al., 2000) has also been found to induce EMT. 
Downregulation of the epithelial marker E-cadherin is a hallmark of EMT. In 
cancers, the E-cadherin promoter is usually hypermethylated or the gene is 
transcriptionally repressed by transcription repressors such as Snail and ZEBl (Yoshiura 
K et.al., 1995; Hajra KM et.al., 1999; Rodrigo I et.al., 1999; Batlle E et.al., 2000; Bolos V 
et.al., 2003). Mutation of the E-cadherin gene, leading to absence or production of non-
functional protein, was also observed, but in less frequent (Thiery JP, 2002). 
30 
Chapter 1: Introduction 
1.6. Aims of Thesis 
The identification of frequent upregulation of GEF-Hl in HCC cell lines and 
primary HCC tissues in earlier studies of our laboratory has prompted the further 
investigations described in this thesis. 
There were mainly three main objectives of this study. Realizing that the GEF-Hl 
is commonly upregulated in HCC, the first objective was to explore whether copy 
number gains constituted as an underlying mechanism in the induction of increased 
gene expression. Copy number enumeration of GEF-Hl was carried out by FISH and copy 
number assay was also performed using quantitative RT-PCR. The second objective was 
to investigate the functional roles of GEF-Hl in liver tumorigenesis. Stably expressed 
GEF-Hl in an immortalized hepatocyte cell line, MIHA, was used as the study model. 
The third objective was to investigate the biological pathways that possibly underlie the 
GEF-Hl-induced oncogenic functions observed. 
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Chapter 2: MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Chemicals and Reagents 
Chemicals and Regents Company 
25mM Magnesium Chloride (MgCb) Applied Biosystems 
2-Mercaptoethanol Sigma-Aldrich Company 
4',6-Diamidino-2-phenylindole (DAPI) Sigma-Aldrich Company 
40% Acrylamide/bis 29:1 Gel Solution Bio-Rad Laboratories 
Agarose, regular USB Corporation 
Alumin, from bovine serum (BSA) Sigma-Aldrich Company 
Ammonium persulfate (APS) Sigma-Aldrich Company 
Amplicillin USB Corporation 
Bio-Rad Protein Assay (Bradford) Bio-Rad Laboratories 
Chloramphenicol Sigma-Aldrich Company 
Chloroform Merck & Co., Inc 
Dextransulfate Sigma-Aldrich Company 
Diethyl pyrocarbonate (DEPC) Sigma-Aldrich Company 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich Company 
DPX Mountant for histology Sigma-Aldrich Company 
Ethanol Merck & Co., Inc 
Ethylenediaminetetraacetic acid (EDTA) Sigma Chemical Company 
Formaldehyde Sigma-Aldrich Company 
Formamide Millipore Corporation 
Glycerol Sigma-Aldrich Company 
Glycine Sigma-Aldrich Company 
Goat serum Invitrogen Corporation 
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2.1.1. Chemicals and Reagents (coiVt) 
Chemicals and Regents Company 
Hi-Di™ Formamide Applied Biosystems 
Isopropanol Merck & Co., Inc 
Ketamine Alfasan International BV 
LS agar USB Corporation 
LB broth USB Corporation 
Pepstatin A Roche Diagnostics 
Phenyl methyl sulfonyl fluoride (PMSF) GE Healthcare 
PhosSTOP Roche Diagnostics 
Precision Plus Protein™ Standards (Dual Color) BioRad Laboratories 
Protease Inhibitor Cocktail Tablets Roche Diagnostics 
RNase ZAPR Ambion Inc 
Sephadex™ G-50 Fine GE Healthcare 
Sigma H2O Sigma-Aldrich Company 
Skimmed milk Marvel 
Sodium acetate (NaOAc) Sigma Chemical Company 
Sodium chloride (NaCI) Sigma-Aldrich Company 
Tetramethylrhodamine B isothiocyanate (TRITC)- Sigma-Aldrich Company 
labeled phalloidin 
Thiazolyl blue tetrazolium bromide (MTT) Sigma-Aldrich Company 
Triton X-100 Sigma-Aldrich Company 
Trizma base Sigma-Aldrich Company 
TRIZOL® reagent Invitrogen Corporation 
Trypan blue Invitrogen Corporation 
Tween 20 Sigma-Aldrich Company 
Vectorshield anti-fade reagent Vector Laboratories 
Xylene Sigma-Aldrich Company 
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2.1.4. Nucleic Acids 
Buffers Company 
10% SDS solution Ambion Inc 
Cell dissociation buffer (PBS-base) Gibco Invitrogen Corporation 
Dnase buffer Promega Corporation 
PCR buffer Applied Biosystems 
Phosphate buffer saline (PBS), pH 7.4 Sigma-Aldrich Company 
siRNA buffer (5X) Dharmacon, Thermo Fisher Scientific 
Tris acetate EDTA buffer (TAE), pH 7.4 Sigma-Aldrich Company 
Prepared buffers Reagents 




Laemmli sample buffer (5X) (Western) 60mM Tris-HCI 
2% SDS 
25% glycerol 
0.1% bromophenol blue 
5% 2-Mercaptoethanol 
Lower Running Buffer (Western) l .SM Tris-HCI (pH 8.8) 
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2.1.2. Buffers (con't) 
Prepared buffers Reagents 





1% Triton X-100 
1% sodium deoxycholate 
pH 7.0 
Stripping buffer (Western) 65mM Tris-HCI 
2% SDS 
lOOmM 2-Mercaptoethanol 
Tris buffered saline (TBS) ISOmM NaCI 
SOmMTris 
(pH 7.5) 




Upper Stacking Buffer (Western) I M Tris-HCI 
(pH 6.8) 
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2.1.4. Nucleic Acids 
Reagents and culture flasks Company 
DMEM Gibco Invitrogen Corporation 
6.5mm Transwell® with 8.0|im Pore Corning Incorporated 
Polycarbonate Membrane Insert 
Fetal bovine serum (FBS) Gibco Invitrogen Corporation 
Geneticin (G418) Gibco Invitrogen Corporation 
L-GIutamine 200mM (lOOX) Gibco Invitrogen Corporation 
Matrigel Invasion Chambers in two 24-well Becton Dickinson 
plates, 8.0|im 
MEM Non-essential amino acids solution lOmM Gibco Invitrogen Corporation 
(lOOX) 
Opti-MEMRI Reduced Serum Medium Gibco Invitrogen Corporation 
Penicillin-Streptomycin, liquid contains 10,000 Gibco Invitrogen Corporation 
units of penicillin and lO^OOOjig of streptomycin 
Petri-dish (60, 100, 150mm) BD Labware Company 
Tissue culture dish (150, 100, 60mm) Becton Dickinson 
Tissue culture plate (96-, 24-, 12- and 6-well) Becton Dickinson 
Trypsin-EDTA Becton Dickinson 
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2.1.4. Nucleic Acids 
Nucleic Acids Company 
1 kb Plus DNA Ladder Gibco Invitrogen Corporation 
All custom designed primers/oligos Gibco Invitrogen Corporation 
BAC clone (RP11-110A23) Vysis Inc., Downers Grove, IL 60515 
BAC clone (RP11-243J18) Invitrogen Corporation 
Biotin-16-dUTP Roche Diagnostics 
cDNA clone for GEF-Hl (MGC:21557 IMAGE Invitrogen Corporation 
ID:4157775) 
Deoxynucleotide Trisphosphate Set, PCR grade Boehringer Mannheim 
Digoxigenin-ll-dUTP Roche Diagnostics 
Human Cot-1 DNA Gibco Invitrogen Corporation 
Human normal total liver RNA Ambion Inc 
Human normal total liver RNA Clontech, Becton Dickinson 
Human normal total liver RNA Stratagene, Agilent Technologies 
ON-TARGET plus siControl Non-targeting Pool Dharmacon, Thermo Fisher 
Scientific 
ON-TARGET plus siRHOA Dharmacon, Thermo Fisher 
Scientific 
pcDNAB.l (+) Invitrogen Corporation 
Salmon Testes DNA Sigma Chemical Company 
TaqMan® probes (inventory) Applied Biosystems 
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2.1.4. Nucleic Acids 
Enzymes Company 
AmpliTaq Gold DNA polymerase Applied Biosystems 
DNA polymerase USB Corporation 
Dnase Promega Corporation 
DNasel Boehringer Mannheim 
Exonuclease I (Exol) USB Corporation 
NotI New England Biolabs 
Pepsin Boehringer Mannheim 
Pfu DNA polymerase Stratagene, Agilent Technologies 
Protease K Qiagen 
RNase Boehringer Mannheim 
RNase A Roche Diagnostics 
RQl RNase-free DNase Promega Biotech Co., Ltd 
Shrimp Alkaline Phosphatase (SAP) Roche Diagnostics 
T4 DNA ligase Invitrogen Corporation 
Xbal New England Biolabs 
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2.1.4. Nucleic Acids 
Equipment Company 
1330GX Incubator SLShel Lab. 
7900HT Fast Real-Time PGR System Applied Biosystems 
ABI PRISM® 3100XL Genetic Analyzer Applied Biosystems 
Centrifuge 5415R Eppendorf International 
Gene Amp PGR System 9700 Applied Biosystems 
Leitz DM RB fluorescence microscope Leica Corporation 
LSM 5 PASCAL Carl Zeiss 
ND-1000 UV-VIS Spectrophotomer NanoDrop Technolgies 
ECLIPSE TSlOO Nikon Instruments Inc. 
OmniSlide Thermal Cycler In Situ PGR System Thermo Electron Corporation 
StepOnePlus Real-Time PGR System Applied Biosystems 
Thermomixer 5435 Eppendorf International 
Victors™ multilabel counter Perkin Elmer 
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2.1.4. Nucleic Acids 
Kits Company 
BigDye Terminator Cycle Sequencing Kit Applied Biosystems 
Cell proliferation ELISA (BrdU) (colorimetric) Roche Diagnostics 
TaqMan® Copy Number Assays Applied Biosystems 
ECL plus™ Western blotting detection reagents GE Healthcare 
ECL Western blotting detection reagents GE Healthcare 
Nanojuice Transfection Reagent Novogen 
PureLink™ HiPure Plasmid DNA Purification Kits Invitrogen Corporation 
QIAamp DNA Mini Kit Qiagen 
QIAGEN® Plasmid Maxi Kit Qiagen 
QIAGEN® Plasmid Mini Kit Qiagen 
QIAquick Gel purification Kit Qiagen 
SYBR Green PCR Reagents Applied Biosystems 
TaqMan® Universal PCR master mix. Applied Biosystems 
with AmpErase UNG 
TaqMan® Reverse Transcription Reagents Applied Biosystems 
TOPO TA Cloning Kit Invitrogen Corporation 
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2.1.4. Nucleic A c i d s 
Antibodies Company 
a-catenin Rabbit polyclonal Cell Signaling Technology 
Anti-Avidin Sigma-Aldrich Company 
Antibody Alexo-Fluro® 488 Invitrogen 
Anti-mouse conjugated HRP IgG Santa Cruz Biotechnology 
Anti-rabbit conjugated HRP IgG Santa Cruz Biotechnology 
Anti-rabbit, TRITC conjugate Sigma-Aldrich Company 
Claudin Rabbit polyclonal Cell Signaling Technology 
Cytokeratin 18 Mouse monoclonal Dako 
E-Cadherin Mouse monoclonal (IF) Zymed, Invitrogen Corporation 
E-Cadherin Rabbit monoclonal Cell Signaling Technology 
GAPDH Mouse monoclonal Chemicon, Millipore Corporation 
y-catenin Rabbit polyclonal Cell Signaling Technology 
GEF-Hl Rabbit monoclonal Cell Signaling Technology 
Anti-DIG (developed in Mouse) Sigma-Aldrich Company 
Phalloidin-TRITC conjugate Sigma-Aldrich Company 
Anti-Mouse IgG, TRITC conjugate (developed in Sigma-Aldrich Company 
Rabbit) 
RhoA Rabbit monoclonal Cell Signaling Technology 
Snail Rabbit monoclonal Cell Signaling Technology 
TCF3 Rabbit monoclonal Cell Signaling Technology 
ZEBl Rabbit monoclonal Cell Signaling Technology 
ZEB2 Rabbit polyclonal Abeam pic. 
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2.1.9. Software and Web Resoreces 
Software and Web Resources Company 
ABI PRISM® 3130 Genetic Analyzer Applied Biosystems 
Data Collection Software v l . l 
Adobe Photoshop CS ver 8.0 Adobe System Incorporation 
AxioVision LE Rel 4.5 Carl Zeiss 
BioEdit Sequence Alignment Editor Tom Hall, Ibis Biosciences, Carlsbad, CA 
CopyCaller™ Software Applied Biosystems 
Cytovision version 3.1 Applied Imaging Ltd.). 
DNA sequencing analysis software v3.7 Applied Biosystems 
ExPASy Proteomics Server http://www.expasy.ch/tools/sim-prot.html 
GraphPad PRISM ver 3.0 GraphPad Software Incorporation 
LSM 5 PASCAL Carl Zeiss 
LSM Image Browser Carl Zeiss 
National Center for Biotechnology http://www.ncbi.nlm.nih.gov/ 
Information (NCBI) 
NCBI Blast 2 http://blast.ncbi.nlm.nih.gov/ 
Primers http://frodo.wi.mit.edu/primer3/ 
SDS Software v2.1 Applied Biosystems 
Squence Scanner vl.O Applied Biosystems 
StepOne™ Software v.2.1 Applied Biosystems 
UCSC Genome Bioinformatics http://www.genome.ucsc.edu/ 
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2.2. Fluorescence In Situ Hybridization (FISHl 
2.2.1. Probe Preparation 
2.2.1.1. Bacterial Artificial Chromosome (BAC) probe preparation 
Verified commercial BAC clones (Invitrogen, Carlsbad, CA) for region of GEF-Hl 
(RP11-243J18) and internal reference on chr.lp31 (RP11-110A23) were streaked on LB 
plate containing lOOpig/ml chloramphenicol and incubate at 37°C for 16hr. Single colony 
was picked and cultured in LB broth with lOO^ig/ml chloramphenicol for 16hr at 37°C 
with shaking. BAC was extracted using PureLink™ HiPure Plasmid DNA Purification Kits 
(Invitrogen, Carlsbad, CA) and the quantity of BAC was determined. 
2.2.1.2. Nick translation 
Fifty microliter reaction mixture containing Ipig BAC DNA, lOX reaction 
buffer, G[i\ 2mM dNTPs, 2^1 labeled-dUTPs (biotin-16 labeled for green signal and 
digoxigenin-11 labeled for red signal), S^il DNasel (1/250U) and l^il DNA Polymerase 
(11.8U/nl) was incubated at 15°C for l.Shr, followed by 4°C to stop the reaction. The 
size of DNA fragments (200-500bps) of nick translation products were verified by 
agarose gel electrophoresis. 2.5^1 of 0.2M EDTA, 20^1 of l^g/|il Human Cot-1 DNA and 
l\i\ of 10.6ng/[il salmon testes DNA, were then added to the whole reaction mixture. 
7.15^1 of 3M sodium acetate and of 100% ethanol were added to precipitate the 
BAC probe at -20°C for overnight. DNA mixture was centrifuged at 13,200rpm, at 4°C for 
30min. The BAC pellet was washed by cold 75% ethanol twice and air dried at room 
temperature. The probe was reconstituted by 4^1 of 50% formamide, 10% 
dextransulfate in I X SSC and stored at -20°C. 
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2.2.2. Hybridization 
Interphase or metaphase (for XY male chromosome of normal lymphocyte in 
testing probe specificity only) chromosomes spread on glass slides were treated with 
l l l ig/ml of pepsin at 37°C for 3-5min, depending on the mass of cytoplasmic content. 
The slides were dehydrated by ice-cold 70%, 80% and 100% ethanol series for 2min each, 
followed by air dried at room temperature. The chromosomes on slides were then 
denatured by 70% formamide (pH 7.7) for 90sec at 64°C to 72°C, depending on 
chromosome morphology. The slides were dehydrated and air dried again as described 
above. 
The labeled probes were denatured at 95°C for 5min, then immediately chilled 
on ice for 5min and pre-warmed at 37°C for 30min. After mixing, two labeled probes 
were then applied onto the denatured chromosomes and incubated at 37°C for 24 to 
48hr in a dark humid chamber. 
Post-hybridization washes were carried out in 50% formamide in 2X SSC at 37°C 
for 5min and then 2X SSC at 37°C for 5min. The chromosomes were non-specifically 
blocked by 3% skimmed milk (Marvel, Dublin, Ireland) at 37°C for 30min. Conjugate 
components (antibodies or fluorescently-tagged avidin) (TableZ.l) in 1% milk were then 
applied to the chromosomes and they were incubated at 37°C for Ihr, followed by 4X 
SSC with TweenZO washing at room temperature for 5min with gently agitation. The 
steps of applying conjugate components and washing were repeated. Primary, 
secondary and tertiary conjugate components were applied in sequence (Table2.1). 
Finally, chromosomes were counterstained by DAPI with Vectorshield anti-fade reagent 
(Vector Laboratories). Hybridization signals were evaluated under a fluorescence 
microscope (Leica). Images were captured through a cooled CCD camera by the 
Cytovision version 3.1 (Applied Imaging Ltd.). 
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Conjugation Biotin Digoxigenin (DIG) 
, , � Anti-DIG (developed in Mouse) 
Primary FTIC-Avidin 1:300 ^ ‘ 
(1:100) 
, , , � Anti-Mouse IgG, TRITC conjugate 
Secondary Anti-Avidin 1:100 � 5 
(developed in Rabbit) (1:100) 
, , � Anti-rabbit IgG, TRITC conjugate 
Tertiary FTIC-Avidin 1:300 ^ � 5 
(1:100) 
Table2.1 Primary, secondary and tertiary conjugate components for detecting and 
amplifying biotin-16 or digoxigenin-11 labeled dUTPs. Dilution ratios are shown in 
brackets. 
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2.3. Genomic DNA extraction 
Genomic DNA used in the copy number assay and GEF-Hl exon sequencing was 
extracted from lymphocytes, in-house established HCC cell lines (in exon sequencing 
only), primary HCC tissues and their adjacent non-tumoral liver by QIAamp DNA Mini Kit 
(Qiagen, Valencia, CA) according to the manufacturer's protocol. 
The primary HCC tissues and their adjacent non-tumoral liver were collected 
from HCC patients who underwent liver resection at the Prince of Wales Hospital, Hong 
Kong. A diagnosis of HCC was confirmed by histology examination. 
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2.4. Copv number analysis 
TaqMan® Copy Number Assays was used to determine the copy number of GEF-
H l in the genome. This assay allows the detection of the GEF-Hl and the internal 
reference [Ribonuclease P RNA component H I (HIRNA) gene (RPPHl) on chr. l4qll .2.] 
in a single reaction. Ten nanogram of genomic DNA (gDNA) was added to the 10|il 
reaction mixture containing S[i\ of 2X Taqman® Universal Master Mix with AmpErase 
UNG, 0.5til of 20X TaqMan® Copy Number Assay probe for GEF-Hl and 0.5|il of 20X 
TaqMan Copy Number Reference Assay probe. Each gDNA sample was quadruplicated 
and no DNA control reactions were also included. The reaction was performed in 384-
well optical tray and the thermal cycling conditions were as follows: 95°C for lOmin, 
followed by 40 cycles of 95°C for ISsec and 60°C for Imin. The emission intensity was 
detected by the 7900HT Fast Real-Time PCR System with SDS Software v2.1 (ABI, Foster 
City, CA). The results were analysed by CopyCaller™ Software (ABI, Foster City, CA). 
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2.5. Exon Sequencing analysis 
2.5.1. PCR amplification of GEF-Hl exons 
The GEF-Hl exons in the genomic DNA of samples were amplified by polymerase 
chain reaction (PCR). 25^il of reaction mixture contained lOOng DNA sample, 2.5^1 lOx 
PCR buffer, 2^1 of 25mM MgCb, 0.5|il dNTP mixture, 0.2U AmpliTaq Gold DNA 
polymerase and 5 picomole for each of forward and reverse primers. The thermal 
cycling conditions for 30 cycles were as follows: 30sec at 94°C, annealing at 55-62°C for 
30sec and extension at 72°C for Imin. The primer sequence and the annealing 
temperature are shown in Table 2.2. Before subjecting to the cycle sequencing, the PCR 
products were treated with exonuclease I (Exol) and shrimp alkaline phosphatase (SAP) 
at 37。C for ISmin and then 80°C for ISmin to remove leftover primers and dNTPs. 
2.5.2. Cycle sequencing 
The DNA sequencing was performed using the BigDye Terminator Cycle 
Sequencing Kit (ABI, Foster City, CA). In lOfil of sequencing reaction, 2^1 of PCR product 
or plasmid (for GEF-Hl construct described in section 2.6.2. only) was mixed with 3.2 
picomole of primer, 2|il 5x sequencing buffer and 2ii l Big Dye. The thermal cycling 
conditions for 45 cycles were as follows: Im in at 96°C, annealing at 50°C for 5sec and 
extension at 60°C for 4min. The products were purified with Sephadex^^ G-50 (GE, 
Piscataway, NJ) fine column to remove any unincorporated nucleotides. Then the 
purified product was denatured at 95°C for 5min with lO^il Hi-Di^'^ formamide (ABI, 
Foster City, CA). The denatured DNA was chilled on ice prior to the sequencing analysis 
by ABI PRISM® 3100XL Genetic Analyzer (ABI, Foster City, CA). The sequences were 
extracted and analysed by ABI PRISM® 3130 Genetic Analyzer Data Collection Software 
v l . l and DNA sequencing analysis software v3.7 (ABI, Foster City, CA). The NCBI Blast 2 
and BioEdit Sequence Alignment Editor were used for sequence alignment while 
Sequence Scanner vl.O was used to visualize the sequence. 
49 
Chapter 2: Materials and Methods 
GEF-Hl Primer Sequences 3') Product Annealing 
Exon size temperature 
(bps) (°C) 
1 Forward: TTGGAAAACCCCTGACCAC 238 61.7 
Reverse: AG G GTCCTCTCCCCTC ACT 
2 Forward: GATGTGTGTTTCAGGAGGAGACT 232 57.8 
Reverse: CAGAACAGAGGAGACGTAGGATAGA 
3 Forward: GGTGTGAGGACTCTTGACATGAT 161 60.8 
Reverse: CCTACTTTTG CTCACCATCTGTATC 
4 Forward: CTGGCTTTAGCTAGACACTTCTCAT 158 62.0 
Reverse: ACAAAACCATAG CCTAG ACCCTATT 
5 Forward: TCI I I I ICTTCATTTCCAGCATTAC 165 57.8 
Reverse: CTGACTCCTACCTTGGCCTTT 
6 Forward: CTCACTTCCTCTCCCTCTCATC 201 62.0 
Reverse: ACTCTCAGGGTCCAAACAACTTAC 
7 Forward: GAGGAGATGGGTGTCTGCAT 151 62.0 
Reverse: CTTCTGCTTGACCTTGGTACAGTT 
8 Forward: ATTCTTGGTATCTCTCTCCTGCTCT 219 62.0 
Reverse: AATCAAGAAGAGGAAGGTGCTATG 
9 Forward: AGAGTCTGATGTTTGCCTGCT 219 62.0 
Reverse: CTCCACTG CCACACTCTCTG 
10 Forward: CTCCACTTTCTTCAGACATTTCAA 200 62.0 
Reverse: CTACTCCCACCAGCCTCTCAT 
11 Forward: AATGTCCAG CAG AG GTAATCTACAG 208 62.0 
Reverse: GTAG ATAAACAG G ACCTG GTG AAG G 
12 Forward: CCACAGAGCTAATCCAGACAGAG 307 62.0 
Reverse: AGTCACACCTCCTTCCATGAAT 
13 Forward: AGGAGGCCAGAGGTGTGTC 287 63.2 
Reverse: GTG CAG CTCACAG G CACTAC 
Table2.2 Primer sequence for PCR of GEF-Hl exons. 
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GEF-Hl Primer Sequences 3') Product Annealing 
Exon size temperature 
(bps) TO 
14 Forward: CTCCTCCCTTGTAGAAAGTGACC 208 60.8 
Reverse: GTCATACCG AG CCTTTCCTCAC 
15 Forward: AG CCTCTAAAG GTG G AATCAAG AC 426 62.0 
Reverse: CAAGAGAGGTTGATTCTAAGACCTG 
16 Forward: GACCGTCTAGTGCTGACTGTTCT 172 62.0 
Reverse: GAGACTAAAACACTTGTCTGTGCTG 
17 Forward: CTTAATCCTTCCTTTCCCCTGACT 274 62.0 
Reverse: AGTTCTATGGTTGGGATCTAATGCT 
18 Forward: TAACCTAGCTTCTGTCTCTCAATGG 206 62.0 
Reverse: AGAGCCATCTCATCI I I I lAACAGT 
19 Forward: TCATGTCCTCACTTGTTCCTTATCT 283 60.8 
Reverse: ATTCTGTGACGGTGAGTGCTT 
20-21 Forward: GTGTCATTCCTGTTCTCACCTCTT 376 60.8 
Reverse: AGAACCTCTTGAGGACCTACCC 
22-23 Forward: AG G ATCG AAATG G AAATCAG C 303 62.0 
Reverse: TACTGACCTGTAGGCCATGTAGAAG 
24 Forward: TAGAAGAGCACAGGGGTTCTGATAA 549 62.0 
Reverse: CCATGGACCCTTATGTCCAC 
25 Forward: CAGAACCTCCAATCTTCACACTACT 278 62.0 
Reverse: CACTCTACCTCTGGTCCATGTCT 
2 6-A Forward: AGTCTCTG CTAACTCACTG G CTTT 431 55.6 
Reverse: ATGTCCCTG GTCCTTTAAATCTC 
26-B Forward: G AG ATTTAAAG G ACCAG G G ACAT 466 62.0 
Reverse: CTTCGATCTCTAATTGCCTACGAT 
26-C Forward: ATCGTAGGCAATTAGAGATCGAAG 437 62.0 
Reverse: CTTTCAG AG G AACTTAG GTCACTG C 
Table2.2(cont.) Primer sequence for PCR of GEF-Hl exons. 
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2.6. Ectopic expression of GEF-Hl in immortalized hepatocyte cell line 
2.6.1. Construction of GEF-Hl expressing vector 
A full length cDNA clone (MGC:21557 IMAGE 10:4157775) encoding human GEF-
H l (Accession No. BC020567) was purchased (Invitrogen). Pfu DNA polymerase 
(Stratagene, Aligent, Cedar Creek, TX) and designed primers were used in PCR with 
annealing temperature 60°C for 3〇sec, extension at 72°C for 4min. NotI and Xbal 
restriction enzyme sites were inserted at the N-terminal and C-terminal respectively of 
the GEF-Hl cDNA sequence. The PCR product of GEF-Hl gene coding sequence with the 
insertion of N-terminal NotI and C-terminal Xbal linkers was around 3 kb. The primers 
for cloning are listed in Table2.3. 
2.6.2. Sub-cloning 
The PCR product and the pcDNAS.l vector were double digested by NotI and 
Xbal at 37°C overnight, followed by purification using QIAquick PCR Purification Kit 
(Qiagen, Valencia, CA). The PCR product (insert) was ligated to the vector, where their 
molar ratio was 10 to 1, by T4 DNA Ligase (Invitrogen, Carlsbad, CA) at 16°C overnight. 
Ligation product was heat shock transformed into TOP-10 E.coli cells (Invitrogen, 
Carlsbad, CA) at 42°C for 45sec. After recovered in glucose-rich SOC medium at 37°C for 
Ihr , the cells were selected on the LB agar plate with amplicillin (50 ^il/ml) (Sigma-
Aldrich, St. Louis, MO) overnight. Ten colonies were picked and checked for the 
presence of insert by PCR. Colonies with insert were inoculated in LB broth with 
100|il/ml amplicillin for overnight and subjected to plasmid extraction by MiniPrep kit 
(Qiagen, Valencia, CA). The sequences of plasmids were verified by cycle sequencing as 
described in section 2.5.2. and those verified colonies were subjected to large scale 
preparation of plasmid using MaxiPrep kit (Qiagen, Valencia, CA). The sequencing 
primers are listed in Table2.3. 
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2.6.3. Transfection and clonal selection 
Immortalized hepatocytes, MIHA, were transfected with the plasmid (pcDNAB.l-
GEF-Hl or pcDNA3.1-vector) using Nanojuice Transfection Reagent (Novogen, North 
Ryde, NSW, Australia). After 24hr, MIHA cells were recovered in DMEM/FBS medium for 
another 24hr. They were then selected in medium containing 1% G418 (Gibco Invitrogen, 
Carlsbad, CA) for three weeks. After the selection, individual clones were selected and 
expanded separately. Finally, one vector control clone (Vec-Ctrl) and two ectopic GEF-
H l expression clones (GEF-Hl-cl and GEF-Hl-c2) were used in the following studies. 
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Primer name Sequence 3'} Tm (°C) 
Cloning (Notl) GEF-Hl-forward ATAAGAATGCGGCCGCTATGAAGGAAGCCAAGGATGC 80.6 
(Xbal) GEF-Hl-reverse GCTCTAGACCCTCAGTAATGTTCTTCAGTGG 67.9 
Sequencing GEF-Hl seq—1 GGAGACTCATCATTGAAATGTCC 59.8 
GEF-Hl seq_2 GGACATTTCAATGATGAGTCTCC 59.8 
GEF-Hl seq_3 CTCAGTGACATCCATACACGCT 60.2 
GEF-Hl seq_4 GCTAGTGAAGGAGCTGCTGTC 59.4 
GEF-Hl seq_5 GAGATGTACGAGGTGCACACAG 60.8 
GEF-Hl seq_6 GGAGTGGAACTGCTCTTGACAC 61.3 
GEF-Hl seq_7 AGGAGGAGCTACGGCGCT 62.5 
GEF-Hl seq_8 AAGGTAGCAGCCGTCTGTCTC 61.0 
Table2.3 Primer sequence for GEF-Hl cloning and cDNA sequencing. 
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2.7. Gene Expression Analysis by Quantitative RT-PCR 
2.7.1. Total RNA extraction 
Cells were washed with DEPC-treated PBS and lysed with TRIZOL® reagent in an 
amount of 1ml per lOcm^ culture dish surface area. After 3min, chloroform was added 
in a ratio of TrizohChloroform equal to 5:1. The mixture was vortexed for ISsec and 
stand for 3min before centrifugated at 12,000g at 4°C for 15min. The upper aqueous 
phase containing total RNA was collected and precipitated by SOO i^l of 100% 
isopropanol at -20°C overnight. The mixture was centrifuged at 12,000g at 4°C for 15min. 
RNA pellet was washed by 75% cold ethanol, air dried and resuspended in DEPC-treated 
water. The total RNA was stored at -SOX until use. 
2.7.2. qRT-PCR analysis for gene expression 
Total RNA from each sample was first treated with DNase to eliminate possible 
carryover of genomic DNA. 10|il total volume of reaction mixture, containing l [ i g of 
total RNA, l U RNase-free DNase and l^il of DNase reaction buffer (Promega, Madison, 
Wl), was incubated at 37°C for ISmin. PCR reaction using primers targeting genomic |3-
globin gene and agarose gel electrophoresis were used to ensure there was no DNA 
contamination of the DNase-treated total RNA. 
The DNase-treated RNA was subjected to RT reaction using the TaqMan® 
Reverse Transcription Reagents (ABI, Foster City, CA) to prepare the first strand cDNA. 
0.2|ig of RNA was mixed with l^i l of lOX TaqMan® RT buffer, 2.2[i\ of 25mM MgCb, 
of lOmM dNTP mixture, O.Sjil of SOpiM random hexamers, 0.2[il of 20U/nl RNase 
inhibitor, and 0.25^1 of 50U/^il MultiScribe™ Reverse Transcriptase. The reaction was 
performed as follows: 25°C for lOmin, 37°C for 60min and 95°C for 5min. All first strand 
cDNA was stored at -80°C until use. 
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One microliters of first strand cDNA were added to of PCR reaction mixture 
containing Spl 2X TaqMan® Universal Master Mix wi th AmpErase UNG or 5|il 2X SYBR 
Green PCR Reagent (for E-cadherin and vimentin only) and 0.5|il of 20X TaqMan® probe 
(ABI, Foster City, CA) (Table2.4) or a pair of specific primers (for E-cadherin and vimentin 
only) (Table2.5). The reaction was performed in 96-well optical tray and the thermal 
cycling conditions were as follows: 50°C for 2min, 95°C for lOmin, followed by 40 cycles 
of 95°C for 15sec and 60°C for Imin. The emission intensity was detected by the 
StepOnePlus Real-Time PCR System with StepOne^'^ Software v.2.1 (ABI, Foster City, CA). 
A no template reaction was included to serve as negative control. All gene expressions 
were normalized with internal reference gene (18S rRNA) to adjust for variations in 
starting template and the relative expression level was determined by the formula of 
2—船(ACt is the threshold cycle different between the target gene and 18S reference 
gene). The determined expression levels of the genes were averaged from triplicate 
reactions. 
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Gene TaqMan® Gene Expression Assay 
GEF-Hl Hs00190884_ml 
SNALl (Snail) Hs00195591_ml 






Table2.4 TaqMan® Gene expression assay. 
Primer Sequences 3') 
Forward: CGCGTCCTGGGCAGAGT 
E-cadherin 




Table2.5 The primers for qRT-PCR. 
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2.8. Western blot 
Western blot was used to determine the protein expression levels. Cells were 
washed with PBS and harvested by Cell Dissociation Buffer (Gibco Invitrogen, Carlsbad, 
CA). The cells were lysed by RlPA lysis buffer, containing protease inhibitors including 
I m M PMSF (GE, Piscataway, NJ), IX protease inhibitor cocktail (Sigma-Aldrich, St. Louis, 
MO), IX pepstatin A (Roche, Penzberg, Germany) and phosphatase inhibitor phosSTOP 
(Roche, Penzberg, Germany). The lysate was incubated in the vertical rotor at 4°C for 
lOmin and centrifuged at 13,200rpm at 4°C for lOmin. The proteins were in the 
supernatant portion and the protein concentration was determined by a standard curve 
plotted by the concentration gradient of BSA (Sigma-Aldrich, St. Louis, MO) in Bradford 
reagent (Bio-Rad, Hercules, CA). 
Thirty micrograms of protein lysates were boiled with Laemmli sample buffer at 
95°C for 5min. The proteins were separated, by SDS-PAGE, on 8-12% of polyacrylamide 
gel according to the molecular weight of the proteins. The gel was equilibrated in 
transfer buffer for 5-lOmin to remove the salts and detergents in electrophoresis buffer. 
The proteins were then transferred onto transfer buffer pre-wetted nitrocellulose 
membrane (GE, Piscataway, NJ) and the membrane was blocked in 5% skimmed milk or 
BSA in TBST at room temperature for Ih r with gently shaking. The membranes were 
incubated with primary antibodies of the target proteins diluted in appropriate 
concentration in 5% skimmed milk or BSA at 4°C overnight with gently shaking 
(Table2.6). The membranes were washed with TBST thrice, for ISmin each time. 
Corresponding horseradish peroxidase (HRP) conjugated secondary antibody were 
added for further 2hr incubation with agitation. Then the membranes were washed 
again with TBST thrice (for ISmin each time) before addition of chem-iluminescent HRP 
substrate, ECL reagents or ECL plus reagents (GE Healthcare) and the signals were 
detected by light-sensitive fi lm (FUJI, Japan). Probing against GAPDH, which is a stably 
expressed protein in cells, was done as the loading control in parallel to the experiment. 
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Molecular 
Primary Secondary 
Antibody Source Weight Company 
dilution dilution 
(kDa) 
GEF-Hl Rabbit 1:1000 1:5000 120 Cell Signaling Technology 
RhoA Rabbit 1:1000 1:5000 21 Cell Signaling Technology 
E-cadherin Rabbit 1:1000 1:5000 135 Cell Signaling Technology 
Cytokeratin 18 Mouse 1:1000 1:5000 45 Dako 
a-catenin Rabbit 1:1000 1:5000 100 Cell Signaling Technology 
y-catenin Rabbit 1:1000 1:5000 83 Cell Signaling Technology 
Claudin Rabbit 1:1000 1:5000 20 Cell Signaling Technology 
GAPDH Mouse 1:25000 1:30000 37 Chemicon, Millipore Corporation 
Snail Rabbit 1:1000 1:5000 29 Cell Signaling Technology 
TCF3 Rabbit 1:1000 1:5000 78 Cell Signaling Technology 
ZEBl Rabbit 1:1000 1:5000 200 Cell Signaling Technology 
ZEB2 Rabbit 1:500 1:5000 136 Abeam pic. 
Table2.6 Antibodies for Western blot. 
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2.9. Functional Analysis 
2.9.1. Cell viability (MTT) assay 
A tetrazolium salt, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyi tetrazolium bromide 
(MTT), was used to assess the cell viability. MTT is the substrate of succinate-
tetrazolium reductase, which involved in mitochondrial respiratory chain and is active 
only in viable cells. Thus, cells had higher viability metabolize more MTT and the product 
formed in a higher rate. 
2x10^ cells were seeded in 96-well culture plates in 5 replicates and 5 individual 
plates were seeded for five-day analysis. In following 5 consecutive days, MTT (Sigma-
Aldrich, St. Louis, MO) was added to each well at concentration of 500|ig/ml and the 
cells were incubated for 2hr. Purple-colored formazan was formed in the reaction and 
the formazan was dissolved in 100[il dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, 
MO). The absorbance at 570nm and the basal absorbance 630nm were quantified by 
micro-plate reader VictorB™ multilabel counter (Perkin Elmer, Waltham, MA) and the 
absorbance different between 570nm and 630nm represented the relative cell viability. 
2.9.2. Cell proliferation assays (BrdU-incorporation) 
Cell proliferation was studied by the detection of incorporation of thymidine 
analogs, 5-bromo-2'-deoxyuridine (BrdU) in the newly synthesized DNA of replicating 
cells. 
Similar with MTT assay, ten wells of 96-well culture plates were seeded with 
2x10^ cells per well and 5 individual plates were seeded for five-day analysis. In 
following 5 consecutive days, BrdU (IX) labeling reagent provided in the Cell 
Proliferation ELISA, BrdU (colorimetric) Kit (Roche, Penzberg, Germany) was added to 
the cells in 5 replicates. The cells in another 5 wells were cultured in medium without 
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BrdU serving as background controls. Following 2hr incubation at 37°C, the cells were 
fixed with FixDenat for 30min to denature the genomic DNA and exposed the 
incorporated BrdU for immune-detection. Peroxidase-conjugated anti-BrdU antibody 
(anti-BrdU-POD), which is a mouse monoclonal antibody specify to recognize BrdU and 
shows no cross reaction with any endogenous cellular components, was then added to 
the cells and incubated for 90min. After washing 3 times with PBS, the peroxidase 
substrate tetramethy-benzidine (TMB) was added and incubated for 5min with gently 
sharking in dark. 25^1 of I M sulphuric acid was added to each well and mixed to stop 
further color development. The color intensity is proportional to the amount of 
peroxidase which reflexes the amount of BrdU incorporation and the proliferation rate. 
The reaction product was quantified by measuring the absorbance different between 
450 nm and the background absorbance 690 nm, and comparing the BrdU experiment 
groups and the background controls groups. 
2.9.3. Mitomycin C (MMC) treatment 
Cell proliferation was stopped by mitomycin C (MMC) (Sigma-Aldrich, St. Louis, 
MO) to eliminate any growth advantages during assays. MMC served as a crosslinker to 
covalently crosslink the complementary stands of DNA that inhibit DNA synthesis and 
cell proliferation. 
After washed by PBS, cells in 80% confluent in 6-well (or 24-well for wound 
healing assay) culture plate were treated with 5^ig/ml MMC in plain DMEM medium at 
37°C for 3hr. Cells were then recovered in DMEM/FBS medium for Ih r at 37°C. The cell 
proliferation rates were verified by BrdU assay and the cell viabilities were determined 
by MTT assay as described in section 2.9.1 and 2.9.2. (Figure2.1). 
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Figure2.1 (A) MTT and and (B) BrdU assays showed that 5^g/ml of mitomycin C was an 
effective dose to blocked GEF-Hl-induced cell growth. 
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2.9.4. Migration and Invasion assays 
Cell migratory ability and invasiveness were assessed by migration transwell 
assay (Corning Inc., Corning, NY) and Matrigel Invasion Chamber (BD, Franklin Lakes, NJ), 
respectively. The tranwell chambers consist of lOum thick polycarbonate membrane 
with pores in Sum diameter while the Matrigel Invasion Chamber consist of 8| im 
diameter pores PET membrane, which coated with a thin layer of MATRIGEL Basement 
Membrane Matrix. 
The chambers held in a 24-well culture plate were first rehydrated in plain 
DMEM at 37°C for 2hr. The MMC pre-treated cells were dissociated and resuspended in 
plain DMEM. Appropriate number of cells (see Table2.7) were seeded in the migration 
and invasion chambers (on the top side of the membrane) in volume of 200^il and 500|il 
respectively. SOOpil and 750nl of FBS supplemented DMEM, serving as chemo-attractant, 
were added to the 24-well culture plate in migration and invasion assay respectively so 
that the lower side of the chamber was immersed in chemo-attractant. The plate was 
incubated at 37°C for appropriate time (see Table2.7). 
After incubation, the non-migrated/invaded cells were removed from the upper 
surface of the membrane by cotton swab. The migrated or invaded cells on the lower 
surface were then fixed in 100% methanol for 5min and stained with Harris's 
haematoxylin (Sigma-Aldrich, St. Louis, MO) for ZOmin. The chambers were rinsed with 
ddhbO and 80% ethonal, followed by subsequently immersed and dehydrated in 80% 
ethanol twice for 2min and 100% ethanol twice for 2min. The dried membranes were 
cut out and mounted on glass slide by DPX mountant (Sigma-Aldrich, St. Louis, MO). The 
results were analysed under the light microscope (400X) and recorded as number of 
migrated/invaded cells per view. At least 20 views were analysed for a chamber. Each 
experiment was performed in duplicate and three independent experiments were 
preformed. 
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Number of cells Time (Day) 
Migration assay 10,000 1 
Invasion assay 50,000 3 
Table2.7 Conditions of migration and invasion assays. 
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2.9.5. Wound healing assay 
When the cells reached 90% confluent in wells of 24-well culture plate, they 
were treated with MMC as described in section 2.9.3.. A straight sharp scratch of about 
1mm width was applied in the middle of the well by a p200 pipette tip and the cells 
were washed by PBS three times. The cells were than incubated in DMEM/FBS at 37°C 
and the wound closures were monitored and images were captured by Nikon ECLIPSE 
TSlOO microscope (Nikon) every 24hr. Duplicate culture was set up in an experiment and 
three independent experiments were performed. 
2.9.6. Transient knock-down of RhoA 
Short interfering RNA (siRNA) was used to knock down RhoA. Vec-Ctrl and GEF-
H l clones were transfected with siRhoA (LU-003860-00) or siControl (Dharmacon, 
Lafayette, CO) using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA). 
Cells were seeded in 24-well plate with DMEM/FBS (without antibiotics) one day 
before transfection. siRNA oligomer was diluted to 40nM in SOpil Opti-MEM® I Reduced 
Serum Medium. l \ i \ of Lipofectamine™ 2000 was diluted in 50^1 Opti-MEM® I Reduced 
Serum Medium and it was incubate for 5min at room temperature. After the 5min 
incubation, the siRNA was combined with the Lipofectamine™ 2000 and incubated for 
further 20min at room temperature after gently mixing. The oligomer-Lipofectamine™ 
2000 complex was then added to each well containing cells and medium. After mixing 
by gently rocking, the cells were incubated at 37°C for 24hr. 
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2.10. Immuno-fluorescent imaging 
3x104 cells were seeded onto a cover slip (22x22 mm) placed in a 6-well plate. 
The cells were rinsed with PBS twice before fixed with 4% paraformaldehyde in dark 
(Sigma-Aldrich, St. Louis, MO) for 15min. Then the cells were gently washed twice with 
PBS for 5min with sharking, and were permeabilized with 0.1% Triton X-100 (Sigma-
Aldrich, St. Louis, MO) for 5min, followed by gently washing with PBS at room 
temperature for 5min on a shaker for two times. Goat serum (Invitrogen, Carlsbad, CA) 
was added for I h r with gently agitation to block the non-specific binding site. Then the 
cells were washed with PBS at room temperature for 5min with gently agitation. 
Primary antibodies (E-cadherin or cytokeratin 18) was then added to cells and incubated 
at 4°C overnight, followed by PBS wash for two times. Corresponding secondary 
antibody Alexo-Fluro® 488 (1:250; Invitrogen, Carlsbad, CA) was added and incubated 
for further 2hr in dark. After final washing in PBS, the cell nuclei were counterstained 
with DAPI (Sigma-Aldrich, St. Louis, MO) in anti-fade solution (Vector Laboratories, 
Burlingame, CA). Images were captured by confocal microscope LSM 5 PASCAL (Carl 
Zeiss, Gottingen, Germany). 
Filamentous actin (F-actins), different from the other target proteins, was 
stained directly by 7.6[iM of TRITC-labeled phalloidin (Sigma-Aldrich, St. Louis, MO) at 
room temperature for 20min in dark. Phalloidin is a toxin from the toadstool Amantio 
pholloides that binds to actin (Cooper JA, 1987). After staining and washing with PBS, 
the nuclei were counterstained with DAPI as described above. The primary and 
secondary antibodies for the immune-fluorescence staining are listed in Table2.8. 
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Primary Secondary 
Antibodies Source antibody antibody Company 
dilution dilution 
E-Cadherin Mouse 1:100 1:250 Zymed, Invitrogen Corporation 
Cyto keratin 18 Mouse 1:500 1:250 Dako 
TRITC-labeled 
--- 1:100000 --- Sigma-Aldrich Company 
Phalloidin 
Table2.8 Antibody list for immunofluorescence staining. 
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2.11. In vivo tumorigenic study of GEF-Hl by subcutaneous injection 
2x10^ cells of MIHA clones (Vec-Ctrl, GEF-Hl-cl or GEF-Hl-c2) in 200^il PBS were 
injected subcutaneously at the dorsal flank with the Vec-Ctrl cells on the left while the 
GEF-Hl clones on the right. The tumor size was monitored for a maximum period of 
three months before termination of experiment. The mice were subjected to euthanasia 
and the xenograft were extracted if one of the following occurred: lost of appetite, 
signifient weight lost, infection occurred during the experiment or when a sizable 
tumour (>1.5cm at any one dimension) was observed. At the end of experiment, mice 
were killed by cervical cord dislocation and the xenografts obtained were measured. 
68 
Chapter 2: Materials and Methods 
2.12. Statistical analysis 
In MTT, BrdU, migration, invasion assays and the qRT-PCR for the EMT markers 
and E-cadherin transcription repressors, unpair Student's t test was used to compare 
the different between the results of Vec-Ctrl and GEF-Hl-cl or GEF-Hl-c2. 
Wilcoxon signed rank test was used to compare the copy number between GEF-
H l and the internal reference on chr . lpSl . 
Statistical analysis was performed by Graphpad Prism 3.0 (GraphPad Software 
Inc., San Diego, CA). A difference was considered significant when a p-value of <0.05 was 
achieved. 
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Chapter 3: RESULTS 
3.1. Verifying copv number gain of GEF-Hl in high GEF-Hl expressing HCC 
In our previous studies of conventional CGH and array CGH, chromosome lq21-
22 amplification (Wong N et.al., 1999) and elevation of GEF-Hl were found to be 
common events in HCC. To confirm the presence of common copy number gains of GEF-
H l in HCC, Fluorescence In Situ Hybridization (FISH) was performed in eight in-house 
HCC cell lines with increased expressions of GEF-Hl (>2 fold expression compared with 
normal liver cells), including HKCI-2, -3, -6, -7, -9, -11, -C2, -C3. The commercial BAC FISH 
probe for GEF-Hl (RP11-243J18) and the internal reference probe on chr. lp31 were 
used. Both were confirmed to be specific with no chimeric signals on normal metaphase 
chromosomes prior to analysis (FigureB.l). Results from FISH showed that all in-house 
cell lines have copy number gain of GEF-Hl relative to the internal reference chr . lp31 
(Figures.2). Also, DNA from 3 pairs of primary HCC tumors and their adjacent non-
tumoral liver were subjected to copy number assay to further investigate the copy 
number change in high GEF-Hl expressing primary HCC tissues. A similar result was 
obtained, showing that a copy number gain of GEF-Hl was found in all primary tumors 
(Figures.3). 
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Key 
Figures.1 Fluorescence In Situ Hybridization (FISH) showed the specificity of FISH 
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Figure3.2.2 The average copy number of GEF-Hl/chr.lp31 in the individual in-house 
cell lines. 
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Figures.3 Copy number assay showed copy number gain of GEF-Hl in primary HCC 
cases when compared with their adjacent non-tumoral liver or normal lymphocyte. N 
and T represent tumor adjacent non-tumoral liver and primary HCC cases, respectively. 
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3.2. Verifying if there is any GEF-Hl exon point mutation in HCC 
It has been reported that C53R mutation in GEF-Hl zinc finger domain reduced 
its binding ability to the microtubule, resulting in activation of GEF-Hl (Krendel M et.al., 
2002). To investigate if there was any GEF-Hl exon mutation in HCC, sequencings of 26 
exons in GEF-Hl were performed in genomic DNA from 5 controls (3 lymphocytic DNA 
and 2 immortalized liver cells), 10 HCC cell lines, and 10 pairs of primary HCC tissues and 
their adjacent non-tumoral liver. 9 HCC cell lines and 6 HCC primary tissues expressed 
high GEF-Hl levels (>5-fold gain), and 1 HCC cell line and 4 HCC primary tissues had 
balanced GEF-Hl expressions when compared with normal liver cells and their adjacent 
non-tumoral liver. Sequencing results demonstrated that no point mutation could be 
found in all samples (Figure3.4 show the sequencing results of a part of the Zinc finger 
domain where C53R mutation was reported). Taken together, this result suggested that 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 3: Results 
3.3. Functional roles of GEF-Hl in HCC 
In an attempt to examine the possible functional role(s) of GEF-Hl in HCC 
development and progression, immortalized hepatocyte cell line, MIHA, were 
transfected with GEF-Hl to establish two stably expressing clones (denoted as GEF-Hl-
c l and GEF-H1-C2). The overexpressed GEF-Hl was validated by qRT-PCR and the 
Western blotting (Figure3.5). 
In MTT and BrdU assay, the GEF-Hl expressing cells showed a higher cell viability 
(p<0.0001) and a higher proliferation rate (p<0.0001) (Figure3.6) than the vector control 
cells (Vec-Ctrl) respectively. In addition, the morphology of GEF-Hl expressing cells was 
greatly different from that of the Vec-Ctrl (Figure3.7). Briefly, the Vec-Ctrl cells were rich 
in cell-cell contacts and grew into a compact round-shaped colony. In contrast to the 
Vec-Ctrl cells, the GEF-Hl expressing cells showed disappearance of cell-cell contact, 
and grew into dispersed colony with elongated cell morphology. 
As GEF-Hl strongly interacts with microtubule and it is a potential regulator of 
cell motility, whether GEF-Hl mediates cell migration was tested. In transwell migration 
assay, matrigel gel invasion assay and wound healing assay, cells were pretreated with 
5j ig/ml of mitomycin C to stop the cell growth and eliminated any GEF-Hl induced-
growth advantage during the assays (Figure2.1). Results showed that GEF-Hl clones had 
a higher migratory ability than Vec-Ctrl (>5-fold) in transwell migration assay (p=0.0009 
and p=0.0003 for GEF-Hl-cl and GEF-Hl-c2 respectively to Vec-Ctrl) (Figure3.8.A). A 
similar result was obtained in matrigel gel invasion assay, ectopic expression of GEF-Hl 
increased the cell invasiveness when compared with Vec-Ctrl (p二0.023 and p<0.0001 for 
GEF-Hl-cl and GEF-Hl-c2 respectively to Vec-Ctrl) (Figure3.8.B). In addition, wound 
healing assay clearly showed that the overexpression of GEF-Hl shortened the 
enclosure time of wound (Figure3.9). Taken together, the results suggested that GEF-Hl 
would promote cell migratory and invasive abilities in normal liver cell. 
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Figures.5 (A) qRT-PCR and (B) Western blotting showed the ectopic expression of GEF-
H l in G E F - H l stable clones. Three independent experiments and three replicates in 
each experiment were performed. 
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Figures.6 (A) MTT and (B) BrdU assays showed cell viability and cell proliferation 
advantages in G E F - H l expressing cell (dash/dot lines). Three independent experiments 
and five replicates in each experiment were performed. 
Student's t test: 
MTT assay: Vec-Ctrl vs GEF-Hl-cl: P < 0.0001; Vec-Ctrl vs GEF-Hl-c2: P < 0.0001; 
BrdU assay: Vec-Ctrl vs GEF-Hl-cl: P < 0.0001; Vec-Ctrl vs GEF-Hl-c2: P < 0.0001 
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Figures.? GEF-Hl induced cell morphological changes. 
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Figures.8 (A) Transwell migration and (B) Matrigel invasion assays showed that 
overexpression of G E F - H l increased the cell migratory and invasive abilities. The right 
panel shows the representative pictures of the migration and invasion assays. Three 
independent experiments and two replicates in each experiment were performed. 
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Figures.9 Wound healing assay showed that GEF-Hl clones had shorter enclosure time 
of wound. Two replicates were performed in each experiment, and one of three 
independent experiments is shown. 
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3.4. GEF-Hl-induced functions were RhoA independent 
RhoA, a downstream target of GEF-Hl, is frequently reported to regulate cell 
migration (Jaffe AB et.al., 2005; Burridge K et.al., 2004). Whether the GEF-Hl-induced 
cell migration and invasion were RhoA dependent was investigated. Surprisingly, 
depletion of RhoA was unable to compromise the GEF-Hl-induced cell migration and 
invasion (Figure3.10-3.12), Also, depletion of RhoA had no effect on GEF-Hl-induced cell 
viability and cell proliferation (Figures.13). Taken together, the results demonstrated 
that GEF-Hl-induced cellular functions were RhoA independent. 
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FigureB.lO Western blotting showed knockdown efficiency of RhoA siRNA. 
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Figures.11 Invasion assay showed that depletion of RhoA had no effect on G E F - H l 
induced invasiveness. Three independent experiments and two replicates in each 
experiment were performed. GEF-Hl-cl: siControl vs siRhoA: p= 0.2739; GEF-Hl-c2: 
siControl vs siRhoA: p= 0.1873 


































































































































































































































































































































































































































































































































































































Chapter 3: Results 
3.5. GEF-Hl Induced Epithelial-mesenchymal transition in HCC 
In attempt to investigate the underlying mechanisms of GEF-Hl on motil ity 
promotion, I focused on the cell adhesion protein, E-cadherin, and its transcription 
repressors including ZEBl, ZEB2, Snail, Slug and TCF3. Results of qRT-PCR showed that 
the expression of E-cadherin was attenuated and the expression levels of E-cadherin 
transcription repressors and an intermediate fi lament vimentin were induced in GEF-Hl 
clones [E-cadherin (GEF-Hl-cl: p<0.0001, GEF-Hl-c2: p<0.0001); ZEBl (GEF-Hl-cl: 
p<0.0001,GEF-Hl-c2: p<0.0001); ZEB2 (GEF-Hl-cl: p<0.0001, GEF-Hl-c2: p<0.0001); 
Snail (GEF-Hl-cl: p<0.0001, GEF-Hl-c2: p<0.0001); Slug (GEF-Hl-cl: p=0.0002, GEF-Hl-
c2: p<〇.0001); TCF3 (GEF-Hl-cl: p=0.0017, GEF-Hl-c2: p=0.0002); vimentin (GEF-Hl-cl: 
p<0.0001, GEF-H1-C2: p<0.0001), all p values are comparing the GEF-Hl clones to Vec-
Ctrl] (Figures.14). Downregulation of E-cadherin together with upregulation of Snail, 
ZEBl, ZEB2 and TCF3 in protein levels were also observed in GEF-Hl expressing cells 
(Figures.15). Down-regulation of E-cadherin is a hallmark of Epithelial-Mesenchymal 
Transition (EMT). To test whether GEF-Hl controls EMT, the expressions of several 
epithelial markers in GEF-Hl expressing cells were determined using Western blotting. 
Claudin, an important component in cell tight junction was also investigated. In Western 
blotting analysis, epithelial markers including E-cadherin, a-E-catenin, y-catenin, 
cytokeratin 18 and claudin were down-regulated upon the ectopic expression of GEF-Hl 
(Figures.16). Also, immunofluorescence (IF) staining was performed to study the cellular 
localization of E-cadherin, cyto keratin 18 and actin filament. Results suggested that the 
expressions of E-cadherin and cyto keratin 18 reduced in cell-cell junction in GEF-Hl 
expressing cells (FigureB.l? and 3.18). Moreover, relocalization of actin fi lament from 
even distribution to edge of cell was observed upon GEF-Hl overexpression (Figure3.19). 
Taken together, downregulation of epithelial markers, together with upregulation of 
mesenchymal marker and E-cadherin transcription repressors in GEF-Hl clones 
suggested that GEF-Hl could promote EMT in liver cells. 
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Figures.14 qRT-PCR showed (A) downregulation of E-cadherin, (B) upregulation of 
vimentin and (C) induction of E-cadherin transcription repressors upon ectopic 
expression of GEF-Hl. Three independent experiments and three replicates in each 
experiment were performed. 
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Figures.15 Ectopic expression of GEF-Hl suppressed the protein expression of E-
cadherin and induced the protein expression of E-Cadherin transcription repressors. 
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Figures.16 Western blot showed the decreased expression of epithelial markers in 


















































































































































































































































































































































Chapter 3: Results 
3.6. G E F - H l induced tumorigenicitv of MIHA cells 
In the in-vivo study, GEF-Hl expressing cells promoted the tumor formation (5/5 
of nude mice), but Vec-Ctrl MIHA cells could not from xenografts (Figures.20). These 
results suggested that GEF-Hl could induce tumorigenicity of MIHA. 
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Figure3.20 In vivo xenograft model showed the GEF-Hl - induced tumorigenicity in 
normal liver cell, MIHA. (A) All (5/5) of the GEF-Hl-c2 cells induced tumor formation 
(right dorsal: red arrow) but none (0/5) of the Vec-Ctrl cell could form xenograft (left 
dorsal: blue arrow). (B) dissected tumors. 
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Chapter 4: DISCUSSIONS 
4.1. High level of GEF-Hl expression in HCC and other cancers 
Hepatocarcinogenesis is a process that involves multiple genetic alterations. 
Chromosome aberrations are a hallmark of solid tumors including HCC. Cytogenetic 
study together with the determination from positional mapping helps to identify novel 
oncogenes and tumor suppressor genes. Chromosome I q gain is frequently observed in 
HCC and is detected in 46-86% of HCC primary tissues (Marchio A et.al., 1997; Kusano N 
et.al., 1999; Sakakura C et.al., 1999; Wong N et.al., 1999; Guan XY et.al., 2000; Chang J 
et.al., 2002; Niketeghad F et.al., 2001; Shiraishi K et.al., 2001; Balsara BR et.al., 2001; 
Midorikawa Y et.al., 2004). Chr.lq gain is considered as one of the earliest chromosome 
change in HCC development. Chr.lq gain is also related to other cancers such as renal 
clear cell carcinoma, squamous cell carcinomas of lung and papillary thyroid carcinoma 
(Gronwald J et.al” 1997; Petersen S et.al., 2000; Kjellman P et.al., 2001). 
The proto-oncogene GEF-Hl is located in the amplicon of chr.lq21-22. It has 
been reported that GEF-Hl played different roles in cancers. For example, it mediates 
the rearrangement of the actin cytoskeleton and focal adhesions in prostate cancer 
(Wells CM et.al., 2010) and modulates the cell invasiveness in brain metastatic 
melanoma (Ridgway LD et.al., 2010). In our previous study, high expression of GEF-Hl 
was found in 92% and 66% of HCC cell lines and HCC primary tissues respectively. The 
high expression of GEF-Hl in primary HCC tissues is associated with low disease free and 
overall survival rates. In addition, high GEF-Hl expression is correlated to the advanced 
AJCC staging (p=0.048) and the presence of micro-vascular invasion (p=0.049), 
suggesting that GEF-Hl is a potential prognostic marker of HCC (Cheng IK et.al., 
unpublished data). 
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Here, I further uncovered that the elevation of GEF-Hl in HCC is largely due to 
the chr. lq22 copy gain. The activation of GEF-Hl from I q genomic gains might be one of 
the mechanisms involving in the early stage of HCC development. 
4.2. GEF-Hl promotes cell motility 
In this thesis, it has been demonstrated that GEF-Hl was found to promoted cell 
migratory and invasion abilities. Relocalization of actin filament from the even 
distribution to the leading edge of cells was also observed upon GEF-Hl overexpression. 
This is the first study to show GEF-Hl could promote cell motil ity in liver cells. Other 
studies demonstrated that depletion of GEF-Hl significantly reduced the migratory 
ability of HeLa cells and impaired wound closure in pigmented retinal pigment 
epithelium (RPE) cells (Nalbant P et.al., 2009, Tsapara A et.al., 2010). Also, GEF-Hl 
targets on RhoA as an activator, which controls the localized RhoA activation at the 
leading edge, and regulated cell migration (Benais-Pont et.al., 2003; Aijaz S et.al., 2005; 
Birkenfeld et.al., 2008; Nalbant P et.al., 2009). But the results found in this study 
demonstrated that depletion of RhoA could not compromise the GEF-Hl-induced cell 
migration and invasion, suggesting the induction of cell motil ity by GEF-Hl is through a 
RhoA-independent pathway. 
It is found that ectopic expression of GEF-Hl could reduce the expression of 
adhesion protein, E-cadherin which is responsible for establishment and maintaining the 
stability of junctions and its loss results in disruption of intercellular contacts and 
enhances the cell motility. Also, several epithelial cell markers were found to be 
decreased in protein level together with the upregulation of mesenchymal cell marker 
vimentin, suggesting that EMT occurred upon ectopic expression of GEF-Hl. 
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EMT, which is characterized by loss of polarized epithelial cell junction 
complexes and remodeling from cytokeratin to vimentin rich cytoskeleton (Sleeman JP, 
Thiery JP, 2011), has active roles in metastatic cascade such as cell migration, invasion 
and intravasation (Thiery JP, 2002; Thiery JP, Sleeman JP., 2006; Gupta GP, Massague J., 
2006). E-cadherin loss seems to be heavily involved in EMT and carcinoma cell 
invasiveness (Birchmeier W., Behrens J., 1994). A direct correlation between E-cadherin 
expression and epithelial phenotype has been demonstrated in vitro (Behrens J et.al., 
1989; Adams CL, Nelson WJ., 1998; Thiery JP, 2002). Disruption of adherens junctions by 
anti-E-cadherin antibodies could induce mesenchymal phenotype (Imhof BA et.al., 1983). 
The mesenchymal phenotype may be associated with invasive behavior in the three-
dimensional collagen gels and heart explants (Chen WC, Obrink B., 1991), but this 
invasive behavior was partially or completely reversed by upregulating E-cadherin 
(Navarro P et.al., 1991; VIeminckx K et.al., 1991). In the results of IF staining, E-cadherin 
not only decreased in expression level, but also lost its edge junctional localization when 
GEF-Hl overexpressed. At the same time, the GEF-Hl clones grew in mesenchymal-cell-
like dispersed colony rather than compact colony as Vec-Ctrl cells. It is proposed here 
that ectopic expression of GEF-Hl promotes the loss of E-cadherin in the cell junction, 
and gain of mesenchymal phenotype, enhancing the cell motil ity and the invasive 
behavior. 
E-cadherin has been reported to be regulated by transcriptional repression and 
promoter hypermethylation (Yoshiura K et.al., 1995; Hajra KM et.al., 1999; Rodrigo I 
et.al., 1999; Batlle E et.al., 2000; Bolos V et.al., 2003). E-cadherin repressors such as 
Snail and ZEBl were upregulated in the GEF-Hl clones. They bind to the E box elements 
of E-cadherin promoter and repress its transcription (Comijn J et.al., 2001; Bolos V et.al., 
2003; Evans AJ et.al., 2007). Besides, these repressors also suppress many target genes 
and induce EMT (Peinado H et.al., 2007). For example, Snail binds and suppresses the 
gene promoters activity of cytokeratin 18 and claudins (De Craene B et.al., 2005), which 
were also downregulated in GEF-Hl expressing cells. Functionally, there are growing 
evidence showing that the repressors were associated with cell invasion, metastasis and 
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a poor clinical outcome in different cancers (Peinado H et.al., 2007). Snail was reported 
to be associated with the invasiveness (by upregulating matrix metalloproteinase 
expression) and poor prognosis in HCC (Miyoshi A et.al., 2005; Sugimachi K et.al., 2003), 
while upregulation of ZEBl resulted in poor prognosis in uterine carcinoma (Spoelstra 
NS et.al., 2006). In addition. Slug and ZEB2 were found to be associated with lymph 
node metastasis, invasion, poor prognosis (Uchikado Y et.al., 2005)and overall survival 
(Maeda G et.al., 2005) respectively in squamous cell carcinoma. 
EMT is a common and important event in cancers. In the GEF-Hl clones, GEF-Hl 
could promote cell migration and invasion through EMT induction, which might likely 
enhance HCC metastasis. 
4.3. GEF-Hl induced tumorigenicitv 
The results in this thesis demonstrated that ectopic expression of GEF-Hl 
induced the tumorigenicity of normal liver cell. A number of study reported that GEF-Hl 
contributed to conversion of normal cells to cancer cells at molecular level. First, murine 
homolog of GEF-Hl, Lfc activated c-Jun N-terminal kinase 1 (JNKl), which is required for 
the full transformation of Ras-induced fibroblasts and melanoma. Also, GEF-Hl induced 
cyclin D1 expression and promoted cell cycle progression through RhoA/ROCK 
dependent pathway in NIH-3T3 cells (Westwick JK et.al., 1998; Coleman ML et.al., 2004; 
Sahai, E. and Marshall, C.J., 2002; ZuberJ et.al., 2000; Birkenfeld J et.al., 2008). However, 
in here, the GEF-Hl-induced cell proliferation and cell viability seems to be RhoA 
independent, suggesting that other mechanism(s) might be involved. A study reported 
that GEF-Hl can exert its regulatory effect through RhoB, but not RhoA. The GEFHl-
RhoB pathway is involved in MHCII expression on dendritic cells which was critical for 
CD4 T-cell activation (Kamon H et.al., 2006). However, the mechanism(s) of GEF-Hl 
regulated functions are still unclear and needed to be further investigated. 
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Chapter 5: CONCLUSIONS AND PROPOSED FUTURE INVESTIGATIONS 
In the previous study of array CGH, together with the current study of FISH and 
copy number assay uncovered that chromosome Iq gain was an activating mechanism 
of GEF-Hl. GEF-Hl induced a number of oncogenic properties in normal liver cell upon 
its ectopic expression. GEF-Hl contributed to the induction of cell viability and cell 
proliferation, it also promoted cell motility and cell invasiveness that were independent 
of the common GEF-Hl downstream effector, RhoA. In addition, ectopic expression of 
GEF-Hl downregulated the expression of E-cadherin and upregulated the expression of 
E-cadherin transcription repressors, suggesting GEF-Hl-induced cell motility might be 
through EMT. Based on these findings, it is proposed that GEF-Hl can promote cell 
migration and invasion by inducing EMT, enhance tumorigenicity of liver cells and may 
predispose to the development of HCC. However, the pathway(s) by which GEF-Hl 
regulates EMT induction is still unclear. 
In attempt to figure out the underlying mechanism on how GEF-Hl control EMT, 
GEF-Hl clone and Vec-Ctrl can be subjected to the gene expression array to identify the 
deregulated genes upon the overexpression of GEF-Hl. In addition, ChIP on ChIP assay 
(gene or promoter targets) or immunoprecipitation assay followed by mass 
spectrophotometry (protein targets) can be performed to determine the potential 
interacting partner of GEF-Hl. 
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